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Bob Dylan T he application of a catheter-based approach to the treatment of arterial occlusion of the lower extremities was proposed by Dotter and Judkins1 nearly 30 years ago; 13 years later, Gruentzig2 demonstrated that similar techniques could be used to achieve nonoperative revascularization in patients with obstructed coronary arteries. Before even one decade had elapsed following Gruentzig's seminal work, the demonstrated utility of percutaneous transluminal coronary angioplasty (PTCA) altogether redefined the management of patients with coronary artery disease (CAD). In contrast, despite three decades of research and development, the role of percutaneous transluminal angioplasty (PTA) in the management of patients with peripheral artery disease (PAD) has remained uncertain, controversial, and the subject of exhaustive debate.
Such contrary attitudes regarding the respective roles of PTCA and PTA in the management of vascular disease are counterintuitive. The relative risks of attempting to revascularize those arteries supplying the electrical and contractile machinery of the heart pose significantly greater risk than attempts to reestablish patency of the arteries supplying muscles of the hips, buttocks, legs, and feet. The risks of PTCA have in most centers required that an operating room and surgical team be kept free for emergency bypass surgery until revascularization has been completed3; in contrast, the lesser risks of PTA have at no time required such a contingency. 4 While restenosis rates as high as 50%5 have from the outset been regarded as an eminently retreatable complication of PTCA, restenosis following PTAtreatable by repeat PTA-has been implicitly equated with graft failure -typically requiring reoperation.
The reasons for such disparate use of percutaneous revascularization within the chest versus below the belt are complicated and many, and the explanation of same would almost certainly defy any meaningful consensus. Only one thing is clear: the future will be different. Thrombolytic therapy is being used on an increasingly widespread basis to convert total occlusions into subtotal or less lengthy occlusions that may be recanalized with less technical difficulty and greater therapeutic efficacy. Plain old balloon angioplasty ("POBA") is neither plain nor old: catheter profiles have been reduced considerably, and the use of novel materials for balloon and guide wire construction has permitted routine access to more remote vascular sites with less risk and greater efficacy. New device technology, the most notable being endovascular prostheses or stents, have already been shown to improve both the shortterm and long-term outcomes of PTA.
The impact of these advances has unavoidable implications for a population whose demographics are being dramatically altered in rapid fashion. People over 65 years of age now constitute 12.4% of the US population, and by 2030 this figure is expected to reach 22%6; it is in this age group that PAD achieves peak prevalence.7 As pointed out in a recent US Public Health Service Document, 8 .... improving the functional independence, not just the length, of later life is an important element in promoting the health of this age group." When PAD results in disabling claudication, patients in this age group may be prevented from experiencing the well-documented benefits9 of exercise and physical activity.
In the days preceding Dotter and Judkins' bold experiment, available options for restoring the functional capabilities of these patients were limited to surgical reconstruction. Given the plethora of comorbid conditions in these so-called "vasculopaths,"10 the risk of precipitating extraextremity vascular complications such as acute myocardial infarction or stroke could not be justified, except in severely debilitated patients. The evolution of technology pioneered by Dotter and Judkins, Gruentzig, and others, however, has now greatly altered the risk/benefit equation: even in patients with coexistent coronary and/or cerebrovascular disease, the most serious risks of vascular surgery can be obviated by judicious application of percutaneous techniques. For many individuals, restored ability to walk the full length of the shopping mall with their spouse and/or friends, complete a round of golf, or walk to the senior citizens center when they cannot afford the luxury of a taxi all become relevant issues in the face of low-risk therapy.
These considerations thus dictate that the contemporary approach to the treatment of peripheral artery disease be carefully, thoughtfully, but unequivocally redefined. The purpose of this article is to make explicit the fact that availability of effective alternative therapy, namely percutaneous revascularization, permits a lower threshold for intervention in patients with PAD than has been traditionally practiced. Deferred evaluation of the patient with angina is uncommon, in part due to the physician's anxiety that the patient is at risk for potentially disabling or even fatal consequences of ischemic heart disease. Deferred evaluation of the patient with claudication carries no such penalty-for the physician. The physician can generally rest assured that in the patient with no rest pain, in whom the ability to walk some limited distance is preserved, there is little risk that limb viability will be jeopardized by failure to obtain appropriate noninvasive tests and/or diagnostic angiography. The price that the patient pays for such a decision, however, may be costly in terms of the limitations that are imposed on many of their otherwise routine activities.
The advent of nonsurgical revascularization mandates that our approach to patients with PAD be redefined to identify those patients in whom a low procedural risk and high probability of technical success warrant intervention for unnecessary disability. Ac 20 The risk/benefit ratio of walking exercise remains beyond dispute among patients in whom symptomatic disability is mild or in whom the risks of operative reconstruction are prohibitive. In patients with disabling symptoms, however, published reports do not support the concept that exercise therapy can achieve the degree of symptomatic benefit typical of successful percutaneous revascularization.
The most concrete evidence of both the benefits and limitations of exercise in treating claudication are to be found in two classic papers published in the late 1960s. The first, by Larsen (Fig 1) . Alternative devices, such as directional atherectomy, have not been widely used for these lesions (except for diagnostic purposes27) for two reasons. First, the relatively large dimensions of devices typically required for all but the smallest iliac arteries create problems for noninflatable devices. Second, the application of endovascular prostheses (stents) to aortoiliac lesions has dramatically changed the short-term (Fig 2) The patient returned to playing golf regularly and has remained asymptomatic during 3 years of follow-up examinations.
technical approaches,33-35 the combination of which has yielded an extremely high procedural success rate. The second issue concerns distal embolization: it has been previously suggested that larger mass required to occlude a large-diameter artery, such as the iliac, might increase the likelihood of embolic complications.36 '37 In patients with an ipsilateral occlusion of the superficial femoral artery (SFA) or one-vessel infrapopliteal runoff, embolic occlusion of the profunda or tibial/peroneal arteries, respectively, may in fact lead to acute limbthreatening ischemia. Prophylactic administration of lytic therapy may therefore be of potential benefit to such patients.
Clearly, the most common indication for iliac angioplasty is claudication. In some patients with claudication, and in rare patients with limb ischemia, the iliac lesion typically coexists with more distal disease involving the SFA and/or infrapopliteal vessels38; in such cases, initial treatment of the iliac obstruction is based on the premise that improving inflow will secondarily improve outflow, either via the profunda in the case of an occluded SFA or by increasing the head of perfusion pressure to that segment of the infrapopliteal circulation that remains patent (Fig 3) . Implicit in this strategy is the lesser degree of technical difficulty, high incidence of procedural success, and low rate of restenosis associated with iliac PTA. Moreover, PTA avoids the complication of iatrogenic postoperative impotence, reported to complicate 10% to 25% of aortoiliac operations.439
A similar strategy underlies the preparatory role of iliac angioplasty in patients undergoing surgical revascularization for treatment of distal disease.38,40,41 Percutaneous revascularization of an iliac lesion may be required to facilitate patency of a downstream femoropopliteal conduit designed to bypass an occluded SFA. Alternatively, nonsurgical revascularization of an iliac site may be used in conjunction with surgery to lower the anatomic site and thereby reduce the risk of operative revascularization in patients judged to be at high risk due to coronary heart disease. In the patient, for example, with a lengthy unilateral occlusion of one iliac artery and less extensive obstruction of the contralateral side, higher-risk aortofemoral bypass surgery may be obviated by percutaneous treatment of the less diseased iliac artery, followed by a cross-femoral graft to the contralateral femoral artery (Fig 4) .
Two additional issues regarding percutaneous treatment of aortoiliac disease deserve specific comment.
The first concerns the role of percutaneous revascularization in modifying the treatment of patients with cardiac disease undergoing vascular surgery.42 Nowhere is this issue more relevant than in patients with coronary heart disease and aortoiliac occlusive disease, in whom abdominal surgery is associated with a marked increase in cardiac morbidity and mortality.10'43-45 Recent work from several groups46'47 has demonstrated the feasibility of intraluminal insertion of a graft-stent prosthesis for the treatment of abdominal aortic aneurysms. Although much less common than aneurysmal dilation, stenoses of the aorta are routinely and effectively treated with (Fig 4) . More common is the situation described above, in which percutaneous treatment of the aortoiliac lesion may permit surgical revascularization to be adjusted one level caudad, obviating the risk associated with aortic-level surgery.
The second issue involves angiographic assessment of iliac stenoses. Clinical experience with intravascular ultrasound has documented the extent to which conventional diagnostic angiography may underestimate hemodynamically significant luminal narrowing in tortuous common and external iliac arteries.51-55 In particular, the ostium of the common iliac as well as the common iliac bifurcation may be problematic in this regard. Intravascular ultrasound permits direct planimetry of luminal cross-sectional narrowing at these sites, obviating the multiple, angulated angiographic views required to unwind and/or eliminate sites of vessel overlap, which may obscure important luminal obstruction. The improved anatomic definition afforded by ultrasound examination may then be used in conjunction with physiologic indexes, including intra-arterial measurement of translesion pressure gradient and/or intra-arterial Doppler measurement flow velocity,50 to identify those lesions that are appropriate for revascularization.
Femoral and Popliteal Arteries
The popliteal artery is the name given to the SFA after it has traversed the adductor canal; previous experience has failed to document any significant differences in either acute or long-term results for percutaneous revascularization of the SFA versus the popliteal arteries; accordingly, both will be herein considered together under the heading of "SFA."
The acute procedural success for percutaneous revascularization of nonocclusive, ie, stenotic, lesions in the SFA using conventional guide wires and standard PTA currently approaches 100%. This contrasts with results of earlier reports56-60 describing acute success rates as low as 72%. It must be recognized, however, that the less optimal results described in these earlier reports reflect two issues. First, many of these reports combined analysis of total occlusions together with stenoses. Second, many of the patients described in these reports ( (Fig 8) . While there is preliminary evidence96 to suggest that the thrombolytic properties of excimer laser radiation may be exploited to reduce the need for thrombolytic therapy in selected patients (Fig 9) The first is the use of hydrophilic wires, the prototype of which is the GlidewireTM (Tervne, Piscataway, NJ). Among 109 consecutive patients at our institution in whom the Glidewire was used to attempt percutaneous revascularization of SFA total occlusions, the Glidewire was successfully advanced across the occluded segment in 107 (98%); balloon angioplasty alone or in combination with directional atherectomy and/or laser angioplasty was then used to complete percutaneous revas- ever, must be tempered by the high frequency of restenosis following percutaneous revascularization of such lesions.56-59,10The basis for the higher incidence of restenosis associated with occluded, as opposed to stenotic, peripheral arteries has been clarified in part by recent in vitro and in vivo analyses. Tobis et al107 performed in vitro studies to determine the mechanism of argon laser-mediated thermal probe recanalization of SFA occlusions 0.5 to 26 cm in length. They observed that regardless of whether the laser was activated, the probe seldom penetrated the central (luminal) portion of a fibrous atheroma; instead, recanalization typically proceeded along an intramural course. We have used catheter-based, intravascular ultrasound to address this same issue in vivo. Three-dimensional reconstruction of ultrasound images from totally occluded peripheral arteries after revascularization confirmed that, in most cases, clinically successful revascularization of totally occluded peripheral arteries does in fact include a significant intramural course.51 108 109 Accordingly, the extent to which these favorable acute, procedural results in patients with chronic total occlusion will ultimately extend the role of percutaneous revascularization remains to be defined. Certainly for patients with nonhealing lesions and/or threatened limb loss in whom the risks of surgery are considered prohibitive or in whom veins are unavailable for distal bypass procedures, percutaneous revascularization of lengthy, occluded segments may facilitate healing. In similar types of patients with rest pain, PTA may be used to achieve pain relief at a lower risk than conventional surgical reconstruction. For patients with less severe symptoms, improved ability to revascularize a chronically occluded artery does not in and of itself constitute a sufficient basis for routine invasive therapy. Until data have been published to document the costbenefit of initial and subsequent revascularization procedures necessary to guarantee reasonable long-term patency, the role of percutaneous revascularization for lengthy, chronic total occlusions must be considered investigational.
Three anatomic issues concerning femoral arterial revascularization deserve additional, specific comment. The first issue involves clinical presentation of embolic complications apparently related to ulcerated and/or thrombotic lesions of the SFA, the so-called "blue toe syndrome." Emboli in such patients were initially inferred to result from friable plaque morphology that posed an unacceptable risk for percutaneous revascularization. It is now clear that such patients can be effectively treated by either PTA or directional atherectomy with both a high degree of procedural success and an acceptably low risk of further embolic complications.10-112 The second involves stenotic and/or occlusive lesions of the common femoral artery. Such lesions certainly may be accessed without great difficulty from the contralateral limb (Figs 6 and 7) . The acute results of common femoral PTA, however, tend to be less predictable, particularly when PTA-induced plaque fractures propogate into the common femoral bifurca- tion, leading to potential compromise of both the SFA and profunda. PTA of the common femoral artery must therefore be undertaken with considerable caution. The third anatomic consideration is the combination of a stenotic profunda with a proximal occlusion of the SFA. Technically satisfactory results of profunda PTA It must be emphasized that the goals of infrapopliteal revascularization often differ from those of above-theknee therapy. Because claudication is rarely the result of infrapopliteal obstruction alone, percutaneous treatment of these sites is typically performed in conjunction with SFA/popliteal revascularization. Even when present as an associated lesion(s), however, the requirement for angioplasty is not automatic: uninterrupted patency of at least one of the three major infrapopliteal arteries is generally sufficient to obviate claudication and/or heal a distal ischemic lesion. In patients in whom infrapopliteal disease coexists with SFA/popliteal disease and in whom at least one of three vessels has no flow-limiting obstruction, it has thus been our practice to limit associated treatment of the infrapopliteal arteries to short (<2 cm) stenoses and/or occlusions if we choose to treat them at all.
More often, however, consideration of infrapopliteal angioplasty is necessary not for symptoms of lower extremity ischemia but for signs of limb ischemia such as nonhealing, ulcerated lesions with or without superimposed infection. In such patients, uninterrupted patency of at least one of the three infrapopliteal arteries may be anticipated to expedite healing of a distal lesion (Fig 11) and/or a residual stump in patients requiring amputation for nonsalvageable tissue. In this group of patients in whom the benefits of successful revascularization far outweigh the risks of a failed procedure, aggressive application of percutaneous revascularization may be expected to achieve extremely gratifying results, even in patients with calcified and/or lengthy total occlusions.
Two points concerning percutaneous infrapopliteal revascularization require special emphasis. First, results previously achieved with conventional wires and balloon catheters do not represent what may be currently accomplished using more contemporary techniques.32 '77 There is little doubt that excimer laser angioplasty (Fig 11) has facilitated percutaneous revascularization of long, total occlusions. Likewise, rotational atherectomy (Fig 12) may play an important role in the treatment of heavily calcified infrapopliteal arteries. Even in the presence of lengthy, multivessel occlusions, demonstrated reconstitution of one or more arteries suggests that percutaneous revascularization of at least one major artery should be possible. Consequently, recommendations based solely on previous experience with standard angioplasty equipment119 deserve to be reconsidered.
Second, the incidence of restenosis -which remains The published experience with stenotic (ie, compromised but nonoccluded) lower extremity bypass grafts is extremely limited and therefore not surprisingly variable. Cohen et al125 used PTA to treat 7 of 29 patients with "impending vein graft failure" and reported a 5-year cumulative patency rate of 43% for this group versus a 5-year cumulative patency of 83% in the remaining 22 patients treated by reconstruction with patch angioplasty. Perler et al126 described a 7-year experience during which a total of 19 grafts were treated by PTA: primary and secondary patency rates at 36-month follow-up were 22% and 27%, respectively. Again, because a primary 5-year patency rate of 62% was achieved in 9 vein graft stenoses revised surgically during the same time period, the authors concluded that surgical reconstruction was preferable to PTA for vein graft stenosis. Bandyk et al127 used PTA to perform 18 of 103 secondary procedures intended to correct primary or recurrent graft stenoses. Their case selection-13 involved an "adjacent artery stenosis," 3 a venous conduit, and 2 an anastomosis-reflected their bias that ".. feeling that percutaneous revascularization of stenotic bypass conduits will for the near future continue to be expanded.
Limited published data137-142 are available regarding comprehensive series of patients in whom occluded bypass conduits have been percutaneously revascularized without preemptive administration of thrombolytic therapy. In most of these previous reports, unspecified numbers of patients were excluded from consideration if the occlusion could not be crossed with a guide wire; lytic therapy was delivered primarily to the origin -as opposed to the "body"-of the thrombus, and/or PTA was performed following lytic therapy only in selected patients. Although not broken down in terms of graft cases versus native arterial sites, McNamara and Fischer137 observed that the ability to completely traverse the occluded site with the guide wire constituted the best single test for predicting the likelihood of recanalizing a given occlusion and obtaining complete clot lysis: in every case in which the guide wire was advanced completely through the occlusion, the ensuing infusion produced complete clot lysis. Among 14 consecutive patients from our own institution in whom a bypass graft was successfully crossed with the GlidewireTM, revascularization was successfully completed in 12 (85.7%).32 The length of the occluded segment measured 3 cm in one patient and was > 10 cm in the remaining 11. Residual luminal diameter narrowing was <30% in all 12 patients. Postprocedural anklebrachial indexes improved from 0.37±+0.08 to 0.82±0.08. Rutherford class also increased by one or more grades in all 12 patients, including 4 who were classified as class 5 or 6 before the procedure.
Our current approach to percutaneous revascularization of occluded grafts exploits not only the ability of the Glidewire' to more readily traverse lengthy graft occlusions, but also profits from the advent of low-profile catheter/wire perfusion systems that permit protracted delivery of lytic therapy directly into the occluding thrombus via side holes in the perfusion instrument. The extent to which these procedural factors were directly responsible for successful revascularization in the above-described cases will require further assessment in a larger patient cohort. It Once having clarified the anatomic basis for claudication, the recommendation to advise percutaneous revascularization is then individualized according to the two considerations indicated above. Two patients, for example, may be similarly limited, and in both, the degree of limitation may be inadequate to justify the risks of vascular surgical reconstruction. Diagnostic angiography may suggest that percutaneous revascularization has a high likelihood of technical success in one patient who may thus be a suitable candidate for percutaneous revascularization. In the second patient, certain risks and a complex of anatomic factors suggesting a low likelihood of acute and/or long-term success may dictate that only surgical revascularization would constitute effective therapy, in which case it may be appropriate to defer the risk of surgery until the patient is more critically disabled. Angiography may thus critically raise or lower the threshold for recommending that an intervention be performed. In previous days, when higher-risk and higher-cost surgery represented the sole option to medical and exercise therapy, it could be reasonably argued that the decision to proceed with angiography could come down to consideration of symptomatic disability only. The option of performing lowerrisk and lower-cost PTA, however, implies that the threshold for responding to a given level of symptomatic disability may be raised or lowered, depending on the extent and complexity of anatomic findings.
Should the patient treated by percutaneous revascularization return with clinical evidence of restenosis, repeat percutaneous intervention is probably indicated for the same reasons that led to the recommendation for the original procedure. A certain proportion of these patients-as has been clearly documented in certain patients undergoing one or more repeat coronary angioplasty proceduresl64,'65-will achieve a satisfactory long-term result following the second intervention. In those who fail repeated percutaneous attempts to achieve long-term patency, the decision to undergo surgical revascularization may involve a reassessment of the patient's anatomy and clinical status.
To adopt this approach with maximum concern for safety and efficacy clearly requires coordinated input from enlightened experts in cardiology, radiology, and vascular surgery. The cost of underuse of such enlightened and coordinated input will be reflected in both loss of dollars and patient-years that might have been otherwise fulfilling and useful.
